evaluating first-line therapies for egfr-mutated nsclc in 2024
Published 1 month ago • 68 plays • Length 1:51Download video MP4
Download video MP3
Similar videos
-
1:09
current and novel treatment approaches for first-line egfr-m nsclc
-
1:30
emerging treatment strategies in egfr-mutant nsclc: osimertinib combinations and beyond
-
59:03
navigating rapid changes in first- and later-line treatment of egfr-mutated nsclc
-
1:26
first line treatment of egfr mutation-positive nsclc
-
1:25
current treatment recommendations and future directions for egfr-mutant nsclc
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
6:08
flaura study: a new standard of care for patients with egfr mutated nsclc
-
7:11
the changing landscape of first line treatment for egfr mutation-positive nsclc.
-
37:23
nsclc: integrating egfr-inhibiting therapies into clinical pathways for first-line treatment
-
6:56
first-line therapy in the patient with egfr-mutant lung cancer
-
0:58
first line treatment options for activating egfr non-small cell lung cancer | dr. alexander spira
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
2:00
choosing first line therapy in egfr mutations
-
1:18
first-line treatment of metastatic egfr-mutated non-small cell lung cancer
-
1:16
dr. wakelee on first-line therapy for egfr-mutant lung cancer
-
2:14
dr. yang on osimertinib as first-line therapy for egfr-positive nsclc
-
2:09
further: firmonertinib in nsclc with egfr pacc mutations
-
5:09
should a third generation egfr inhibitor be first line therapy for egfr mutation-positive nsclc?
-
7:59
dacomitinib beats iressa as first line treatment for egfr mutation-positive nsclc